111 filings
Page 4 of 6
6-K
rdogp5tc8xn e98dah08
9 Oct 20
Current report (foreign)
9:06am
6-K
sf9fi0zb7ivveqlmc
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
6-K
ay874g7 luliaw
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
1937tq
21 Sep 20
Current report (foreign)
4:15pm
6-K
fpwxp40cc9pj79gxc n6
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
zqkptl 4p
11 Sep 20
Current report (foreign)
8:16am
6-K
husl41 smk3qkco
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
7bji6okalruxliza0w9
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
6jru0xj
4 Sep 20
Current report (foreign)
4:01pm
6-K
0cvryub4l377naj u7
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
v0xow533f2 96mr
13 Aug 20
Current report (foreign)
7:30am
6-K
kvxjrr
10 Aug 20
Form 6-K for Zai Lab Limited - August 7, 2020
12:00am
6-K
46w8p9kad7tyrqixoe6
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
z70i lb4uksgk28rol
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am
6-K
22ztsvmdm uh
13 May 20
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
10:22am
6-K
408 9bz5l
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
6-K
nqdahxkp 0mbg6
19 Mar 20
Current report (foreign)
7:53am
6-K
dg2pi
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
6-K
7ljjl07j 328rl
27 Jan 20
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
4:41pm
6-K
1wlofvu8qhtk4v8f
23 Jan 20
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
6:08am